Pharma Current Deferred Revenue vs Cash And Short Term Investments Analysis

0RC6 Stock   75.72  2.97  4.08%   
Pharma Mar financial indicator trend analysis is much more than just breaking down Pharma Mar SAU prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pharma Mar SAU is a good investment. Please check the relationship between Pharma Mar Current Deferred Revenue and its Cash And Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Pharma Mar SAU. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Current Deferred Revenue vs Cash And Short Term Investments

Current Deferred Revenue vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pharma Mar SAU Current Deferred Revenue account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong relationship.
The correlation between Pharma Mar's Current Deferred Revenue and Cash And Short Term Investments is 0.74. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Pharma Mar SAU, assuming nothing else is changed. The correlation between historical values of Pharma Mar's Current Deferred Revenue and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Pharma Mar SAU are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Current Deferred Revenue i.e., Pharma Mar's Current Deferred Revenue and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.74
Relationship DirectionPositive 
Relationship StrengthSignificant

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Pharma Mar SAU balance sheet. This account contains Pharma Mar investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Pharma Mar SAU fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Pharma Mar's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pharma Mar SAU current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Pharma Mar SAU. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At this time, Pharma Mar's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 10.1 M in 2024, despite the fact that Discontinued Operations is likely to grow to (1.9 M).
 2021 2022 2023 2024 (projected)
Gross Profit213.4M182.7M148.5M114.0M
Total Revenue229.8M196.3M158.2M146.3M

Pharma Mar fundamental ratios Correlations

-0.750.810.620.890.35-0.840.680.060.820.160.490.930.08-0.220.340.120.87-0.370.490.99-0.66-0.650.170.570.72
-0.75-0.67-0.11-0.79-0.470.91-0.740.04-0.81-0.1-0.25-0.8-0.370.480.050.17-0.870.520.0-0.760.880.74-0.03-0.68-0.59
0.81-0.670.60.75-0.03-0.690.82-0.070.57-0.160.380.85-0.250.20.430.160.71-0.650.550.82-0.75-0.680.480.380.83
0.62-0.110.60.34-0.1-0.180.240.10.210.180.40.43-0.510.20.540.570.28-0.120.790.61-0.11-0.110.45-0.090.59
0.89-0.790.750.340.46-0.870.730.090.790.110.140.90.25-0.15-0.020.130.88-0.370.120.86-0.67-0.730.250.70.45
0.35-0.47-0.03-0.10.46-0.470.150.360.50.37-0.30.30.78-0.78-0.480.070.440.09-0.390.31-0.27-0.36-0.120.68-0.16
-0.840.91-0.69-0.18-0.87-0.47-0.70.02-0.96-0.11-0.28-0.9-0.450.41-0.080.24-0.930.4-0.13-0.830.770.840.1-0.75-0.56
0.68-0.740.820.240.730.15-0.70.210.55-0.120.220.74-0.020.030.160.030.75-0.910.210.68-0.91-0.670.350.460.63
0.060.04-0.070.10.090.360.020.21-0.020.36-0.21-0.070.21-0.13-0.10.30.01-0.22-0.040.0-0.180.26-0.020.11-0.13
0.82-0.810.570.210.790.5-0.960.55-0.020.210.340.840.5-0.510.15-0.280.9-0.260.190.81-0.65-0.77-0.270.690.5
0.16-0.1-0.160.180.110.37-0.11-0.120.360.21-0.11-0.10.24-0.43-0.280.330.10.23-0.130.040.030.3-0.33-0.08-0.2
0.49-0.250.380.40.14-0.3-0.280.22-0.210.34-0.110.46-0.21-0.050.82-0.350.27-0.210.750.54-0.28-0.11-0.230.110.76
0.93-0.80.850.430.90.3-0.90.74-0.070.84-0.10.460.18-0.150.35-0.090.87-0.450.420.94-0.72-0.830.170.730.74
0.08-0.37-0.25-0.510.250.78-0.45-0.020.210.50.24-0.210.18-0.73-0.38-0.470.270.19-0.480.05-0.17-0.31-0.580.72-0.25
-0.220.480.20.2-0.15-0.780.410.03-0.13-0.51-0.43-0.05-0.15-0.730.290.26-0.37-0.150.29-0.220.240.20.52-0.440.04
0.340.050.430.54-0.02-0.48-0.080.16-0.10.15-0.280.820.35-0.380.29-0.220.05-0.230.940.39-0.13-0.09-0.06-0.030.72
0.120.170.160.570.130.070.240.030.3-0.280.33-0.35-0.09-0.470.26-0.22-0.090.040.060.070.140.250.71-0.3-0.13
0.87-0.870.710.280.880.44-0.930.750.010.90.10.270.870.27-0.370.05-0.09-0.470.140.87-0.76-0.80.040.60.54
-0.370.52-0.65-0.12-0.370.090.4-0.91-0.22-0.260.23-0.21-0.450.19-0.15-0.230.04-0.47-0.21-0.40.820.45-0.33-0.19-0.57
0.490.00.550.790.12-0.39-0.130.21-0.040.19-0.130.750.42-0.480.290.940.060.14-0.210.52-0.14-0.10.13-0.060.76
0.99-0.760.820.610.860.31-0.830.680.00.810.040.540.940.05-0.220.390.070.87-0.40.52-0.67-0.690.190.580.76
-0.660.88-0.75-0.11-0.67-0.270.77-0.91-0.18-0.650.03-0.28-0.72-0.170.24-0.130.14-0.760.82-0.14-0.670.65-0.14-0.53-0.66
-0.650.74-0.68-0.11-0.73-0.360.84-0.670.26-0.770.3-0.11-0.83-0.310.2-0.090.25-0.80.45-0.1-0.690.65-0.15-0.68-0.49
0.17-0.030.480.450.25-0.120.10.35-0.02-0.27-0.33-0.230.17-0.580.52-0.060.710.04-0.330.130.19-0.14-0.15-0.090.19
0.57-0.680.38-0.090.70.68-0.750.460.110.69-0.080.110.730.72-0.44-0.03-0.30.6-0.19-0.060.58-0.53-0.68-0.090.31
0.72-0.590.830.590.45-0.16-0.560.63-0.130.5-0.20.760.74-0.250.040.72-0.130.54-0.570.760.76-0.66-0.490.190.31
Click cells to compare fundamentals

Pharma Mar Account Relationship Matchups

Pharma Mar fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets124.7M330.3M368.4M393.3M341.2M276.5M
Short Long Term Debt Total86.1M56.7M49.3M42.6M43.7M82.0M
Other Current Liab12.6M57.1M45.4M55.1M51.9M54.5M
Total Current Liabilities60.4M94.9M86.3M97.3M95.9M81.0M
Total Stockholder Equity11.4M102.7M177.9M223.0M193.4M203.1M
Property Plant And Equipment Net25.8M25.5M30.6M34.7M47.6M26.1M
Net Debt68.5M(39.5M)(64.0M)(107.2M)(16.4M)(15.5M)
Retained Earnings(69.6M)41.9M121.3M156.5M142.2M149.3M
Accounts Payable16.5M21.0M26.9M27.5M29.2M28.4M
Cash17.6M96.2M113.3M149.8M60.0M53.4M
Non Current Assets Total74.7M84.6M73.2M118.1M88.6M73.5M
Non Currrent Assets Other4.8M100.2M89.4M33.5M1.4M1.3M
Cash And Short Term Investments20.9M195.5M201.9M182.4M162.6M170.7M
Common Stock Shares Outstanding18.4M18.3M18.1M18.1M17.9M19.8M
Liabilities And Stockholders Equity124.7M330.3M368.4M393.3M341.2M276.5M
Non Current Liabilities Total56.8M132.6M104.1M73.0M51.9M78.1M
Inventory8.9M11.9M10.5M27.7M39.3M22.5M
Other Current Assets8.6M14.1M31.9M35.7M23.2M15.6M
Other Stockholder Equity69.8M49.8M45.6M55.4M40.2M38.2M
Total Liab117.2M227.5M190.5M170.3M147.8M159.1M
Total Current Assets50.0M245.7M295.2M275.2M252.6M175.4M
Short Term Debt31.3M16.8M14.0M14.7M14.8M24.0M
Intangible Assets6.1M3.9M3.2M2.6M1.9M1.8M
Short Term Investments3.3M99.3M88.5M32.6M102.5M107.7M
Current Deferred Revenue10.1M52.2M39.6M26.1M25.9M19.8M
Net Receivables13.2M26.7M78.9M29.3M47.8M44.4M
Other Assets47.2M37.9M33.7M30.6M35.1M40.5M
Accumulated Other Comprehensive Income12K15K14K38K19K14.3K
Other Liab2.0M92.7M68.8M45.1M51.8M40.3M
Net Tangible Assets10.5M101.7M176.8M221.8M255.0M267.8M
Deferred Long Term Liab5.2M2.8M2.1M1.4M1.3M1.2M
Property Plant Equipment25.6M24.7M26.9M36.9M42.5M31.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pharma Stock Analysis

When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.